Tuesday morning snapshot

A snapshot of the early morning's equity news and key market movements.

Last night in the US: The Dow Jones closed up 26 points at 16,743, the NASDAQ finished down five points at 4237 and the S&P 500 ended the day up one points at 1924.

This morning in London: The FTSE 100 is currently down 14 points at 6848.

FX and commodities: GBP/USD is up 12 pips at $1.6757, EUR/USD is up seven pips at $1.3604 and USD/JPY is down three pips at ¥102.34. Brent crude is up 11 cents at $108.87 and gold is trading at $1245, up $1.

Stocks: AstraZeneca has announced that the FDA has fast tracked its latest antibiotic drug. More bad news for G4S as a government watchdog is now investigating the company’s activities in Palestine and Israel. Wolseley has stated it expects the next half year to see revenue grow by 4%.  

The day ahead: UK construction purchasing managers index figures are out this morning, along with the eurozone current unemployment rate and yearly flash consumer price index estimates. Later in the afternoon we will see US monthly factory orders.

All figures correct at 8.20am. All times London time.

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.